Orforglipron vs Tirzepatide: What the Research Shows
Orforglipron and Tirzepatide side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Orforglipron if…
- you want an FDA-approved oral option: Foundayo (orforglipron) is labelled, with diet and activity, to reduce excess body weight in adults with obesity or with overweight plus a weight-related condition[6]
- you want an oral option with randomized weight-loss data: Body weight changed by -7.5% (6 mg), -8.4% (12 mg) and -11.2% (36 mg) with orforglipron vs -2.1% with placebo at week 72.[16]
Consider Tirzepatide if…
- you want an FDA-approved product: Zepbound (tirzepatide) is labelled, with diet and activity, for chronic weight management in adults with obesity or with overweight plus a weight-related condition[15]
- you want large randomized weight-loss data (the SURMOUNT program): Mean weight change at week 72 was -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg) with tirzepatide versus -3.1% with placebo.[17]
Spec comparison
Showing 7 of 11 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.
| Field | Orforglipron | Tirzepatide |
|---|---|---|
| Class | Oral small-molecule GLP-1 agonist | GLP-1 / GIP dual agonist |
| Also called | Foundayo, orfo | tirz, tirze, Mounjaro, Zepbound |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | FDA approved (Foundayo, Apr 2026) | FDA approved (Mounjaro, Zepbound) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Half-life | approximately 29 to 49 hoursoral · FDA label (Foundayo) | approximately 5 dayssubcutaneous · FDA label (Mounjaro) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41275875 | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 |
| Human studies we summarised | 14 human (13 randomized or controlled) of 15 summarised | 24 human (22 randomized or controlled) of 30 summarised |
| Typical study doses |
|
|
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
How does orforglipron compare to tirzepatide for weight loss?
No head-to-head trial of Foundayo and tirzepatide is cited. The two meet in a maintenance study, where people previously treated with tirzepatide in SURMOUNT-5 were randomised to orforglipron or placebo.[18]
In that study, tirzepatide-treated participants who had reached a body weight plateau maintained 74.7% of their weight reduction on orforglipron against 49.2% on placebo (model-based estimates).[18]
In orforglipron's own obesity trial, the 36 mg dose gave an average weight change of -11.2% against -2.1% with placebo.[16]
In the separate tirzepatide obesity trial, 15 mg gave -20.9% against -3.1% with placebo. The populations and trials differ, so these are not head-to-head figures.[17]
In the orforglipron obesity trial, the most common adverse events were gastrointestinal effects, mostly mild to moderate.[16]
Daily pill and weekly injection: what the labels say
The Foundayo label says to take it orally once daily, with or without food.[6]
The Zepbound label starts at 2.5 mg injected subcutaneously once weekly for 4 weeks, then raises the dose in 2.5 mg steps after at least 4 weeks.[15]
After an oral dose, the Foundayo label puts the elimination half-life at approximately 29 to 49 hours.[6]
The Foundayo label says that if 7 or more consecutive doses are missed, dose escalation should restart at a lower dose to reduce the risk of gastrointestinal adverse reactions.[6]
Zepbound's label includes moderate to severe obstructive sleep apnea in adults with obesity.[15]
The Foundayo label says concomitant use with another GLP-1 receptor agonist is not recommended.[6]
Tirzepatide's Mounjaro label describes it as acting on two receptors, GIP and GLP-1.[10]
Common questions
Is orforglipron as good as Zepbound?
Orforglipron's own obesity trial reported -11.2% at 36 mg against -2.1% with placebo. No trial cited compares it directly with Zepbound.[16]
Can you switch from tirzepatide to orforglipron?
A maintenance trial tested this after weight had come off: participants kept 74.7% of the weight reduction on orforglipron against 49.2% on placebo.[18]
Orforglipron vs Mounjaro: what is the difference?
Foundayo's label indication is, with diet and activity, to reduce excess body weight and maintain the reduction long term.[6]
Is orforglipron the same as tirzepatide?
No. Foundayo's label describes orforglipron as a GLP-1 receptor agonist, whereas the Mounjaro label quoted in the labels section describes tirzepatide as acting on both the GIP and GLP-1 receptors.[6]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Orforglipron approved as FoundayoFDA · 2026fda.govAccessed 2 Oct 2026
- 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 5World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 6These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial FDA label (Foundayo), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 7Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
- 8Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 41765029Accessed 2 Oct 2026
- 9Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.Lancet (London, England) · 2026PMID 42259339Accessed 2 Oct 2026
- 10These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 11Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 12Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 13Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 14PubMed search: (orforglipron[tiab] OR LY3502970[tiab] OR Foundayo[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 16Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
- 17Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 18Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Nature medicine · 2026PMID 42120723Accessed 2 Oct 2026
Found an error? Report a correction.